News | February 21, 2022
Corbevax receives EUA for 12-18 age group
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
To be marketed by Strides Pharma Inc. in the US market
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
In the interim, Deepak Khanna will lead Human Health International.
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
Subscribe To Our Newsletter & Stay Updated
